Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001200 | 0.87 | ALDH1A1 (0.47) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL1457069 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL15589311 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL9358244 | 0.82 | GABRA1 (0.43) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL1018021 | 0.82 | GABRA1 (0.79) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL1019702 | 0.82 | GABRA1 (0.43) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL11415288 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2MIFATMKMT2A | |
| SCHEMBL8958496 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL15051494 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2ATMKMT2AMEN1 | |
| SCHEMBL508696 | 0.79 | ATM (0.43) | GABRA1GABRB2ATMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084759-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2025-03-13 | — | — | US | claimed |
| CN-117945956-A | Synthesis method of N-trifluoromethyl sulfonamide compound | 南京理工大学 | 2024-04-30 | — | — | CN | claimed |
| CN-109096222-A | A kind of 2,6- accelerine base thiazine chemical synthesis process | 黄石法姆药业股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| CN-105267967-A | Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2016-01-27 | — | — | CN | claimed |
| CN-104415332-A | Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2015-03-18 | — | — | CN | claimed |
| CN-104117064-A | Combined application of isothiocyanate compound and hormone medicine | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2014-10-29 | — | — | CN | claimed |
| US-5043442-A | Process of preparing an isothiocyanate intermediate used in the preparation of xylazine | CHEMSYN SCIENCE LABORATORIES (US) | 1991-08-27 | — | — | US | claimed |
| US-4614798-A | IMPROVED YIELD OF INTERMEDIATE USING TETRAHYDROFURAN OR A MIXTURE OF TOLUENE AND N,N-DIMETHYLACETAMIDE AS SOLVENT | VETAMIX (US) | 1986-09-30 | — | — | US | claimed |
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2025078982-A1 | XYLAZINE HAPTENS, IMMUNOGENS, AND PROTEIN CONJUGATES AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250084759-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2025-03-13 | — | — | US | disclosed |
| US-12221507-B2 | Monobidentate, bis-bidentate, and tetrabidentate guanidine Group IV transition metal olefin copolymerization catalysts | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-11 | — | — | US | disclosed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | disclosed |
| EP-0194112-A1 | 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-09-10 | — | — | EP | disclosed |
| US-4418209-A | ANTIULCER, ANTIARRYTHMIC, ANTIDIARRHEAL, ANTISPASMODIC, ANTIPARASITIC, AND ANTISECRETORY AGENTS | WILLIAM H. RORER, INC. (US) | 1983-11-29 | — | — | US | disclosed |
| US-4313885-A | Furfuryl thiourea compounds | AMERICAN CYANAMID COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4267191-A | BY ADMINISTERING FURFURYL THIOUREA COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
| US-4194008-A | INSECTICIDE, FUNGICIDE, MITICIDE, PARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | GABRA1 3626/4885GABRB2 3271/4885MIF 986/4885 |
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | TST, SLC39A11, SLC39A3 | GABRA1 3181/4885GABRB2 2017/4885MIF 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.